

## list of all pharmaceutical companies and contact details:

## Data from www.clinicaltrials.gov and South African National Clinical Trial Register

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication             | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail         | Locations                                     | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor  | Phase   | Start Date       | Planned Completion Date |
|------------|---|------------------------|--|--|---|--|--|---------|------------------|-------------------------|
| 2016/02/01 | NCT00858364   | Lung Cancer            | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy   | stage IV Non -small cell lung cancer with anemia   | Bloemfontein, Johannesburg, Durban,           | Tel 011 612 8600   | Amgen  | Phase 3 | 01 June 2009     | 01 June 2019            |
| 2016/02/01 | NCT00957086   | Head and Neck cancer   | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer   | after operation, locally advanced head and neck cancer<br>no evidence of distant metastasis.   | Durban, Cape Town                             | Dr Jo Ann James Durban joann@medi.co.za<br>Sheila Visser Durban glanders2@medi.co.za<br>Dr Conrad Jacobs Panorama Conrad.Jacobs@cancercafe.co.za | National Medical Research Council (NMRC), Singapore Innogene Kalbiotech Pte. Ltd | Phase 3 | 01 August 2009   | 01 June 2021            |
| 2016/02/01 | NCT01160211   | Breast cancer          | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | postmenopausal with hormone receptor positive (HR+), HER2-positive metastatic breast cancer (MBC) who have received prior trastuzumab and endocrine therapies. | Cape Town, Durban, Johannesburg, PE, Pretoria | Contact: US GSK Clinical Trials Call Center 00877-379-3718 or GSKClinicalSupportHD@gsk.com   | GlaxoSmithKline  | Phase 3 | 01 May 2011      | 01 December 2017        |
| 2016/02/01 | NCT01200589   | Non-Hodgkin's Lymphoma | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy   | B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy  | Johannesburg, PE, Amanzimtoti                 | GSKClinicalSupportHD@gsk.com   | GlaxoSmithKline  | Phase 3 | 01 October 2010  | 01 September 2020       |
| 2016/02/01 | NCT01242800   | Breast cancer          | Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer  | primary (not recurrent) invasive carcinoma of the breast stage IV  | Pretoria                                      | Contact: Prof Lydia M. Dreosti 012-354-1000  | Eastern Cooperative Oncology Group National Cancer Institute (NCI)               | Phase 3 | 01 February 2011 | 17 July 1905            |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication       | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations   | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor  | Phase   | Start Date      | Planned Completion Date |
|------------|---|------------------|---|--|---|--|--|---------|-----------------|-------------------------|
| 2016/02/01 | NCT01352117   | Kaposi's Sarcoma | Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma  | HIV  | Durban, Johannesburg  | Pauline Vunandlala 011-2768800<br>pvunandlala@witshealth.co.za ; Dr Rosie Mngqibisa 031-2604469<br>mngqibisa@ecarefoundation.com | AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 01 October 2011 | 01 October 2020         |
| 2016/02/01 | NCT01610284   | Breast cancer    | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor                     | Locally advanced or metastatic breast cancer, HER2-negative and hormone receptor-positive status, Postmenopausal woman                                 | Bloemfontein, Johannesburg  | Tel 0113466600   | Novartis Pharmaceuticals Novartis  | Phase 3 | 01 August 2012  | 01 October 2017         |
| 2016/02/01 | NCT01772472   | Breast cancer    | A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Following Preoperative Therapy<br>Not metastatic cancer                            | Johannesburg, Cape Town, Port Elizabeth, Pietermaritzburg, Pretoria | Contact: Reference Study ID Number: BO27938 Tel 011 5025027  | Hoffmann-La Roche German Breast Group NSABP Foundation Inc                               | Phase 3 | 01 April 2013   | 01 March 2023           |
| 2016/02/01 | NCT01846611   | Ovarian cancer   | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer                        | advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer   | Pretoria, Cape Town, Johannesburg, PE, Amanzimtoti, Durban          | Tel 011 518 7000   | Janssen Research & Development, LLC PharmaMar  | Phase 3 | 01 October 2013 | 01 September 2018       |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication    | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations   | Contact (please note some contacts are international) Use NCT number as reference   | Sponsor                            | Phase   | Start Date       | Planned Completion Date |
|------------|---|---------------|--|--|---|---|------------------------------------|---------|------------------|-------------------------|
| 2016/02/01 | NCT01923168   | Breast cancer | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women   | confirmed diagnosis of breast cancer, postmenopausal, no metastasis, operable breast cancer, no diabetes   | Pretoria, Johannesburg  | Tel 0113466600  | Novartis Pharmaceuticals  Novartis | Phase 2 | 01 March 2014    | 01 June 2017            |
| 2016/02/01 | NCT01989676   | Breast cancer | A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)  | First-Line Treatment Of Patients With HER2-positive Metastatic Breast Cancer, not in heartfailure  | Cape Town, Amanzimtoti, Johannesburg, PE, Pretoria                              | Prof L Dreosti<br>Telephone: 012 354 1054   | Pfizer                             | Phase 3 | 01 February 2014 | 01 February 2018        |
| 2016/02/01 | NCT02106546   | Lung cancer   | Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | advanced or metastatic squamous NSCLC that is not amenable to surgical resection or radiation  | Durban, George, Johannesburg, Port Elizabeth, Pretoria                          | Rachelle Branford<br>Telephone: 011 858 2163/<br>011 858 2037<br>Contact: Suzanne El-Hadi,<br>MS 001 514-832-7060<br>suzanne.el-hadi@abbvie.com | AbbVie                             | Phase 3 | 01 April 2014    | 01 April 2017           |
| 2016/02/01 | NCT02125461   | Lung Cancer   | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer  | locally advanced, unresectable, Stage III lung cancer, already had 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.          | Bloemfontein, Cape Town, Johannesburg, Pretoria, Vereeniging                    | Prof P Ruff Telephone:<br>+27114884452  | AstraZeneca                        | Phase 3 | 01 May 2014      | 01 January 2020         |
| 2016/02/01 | NCT02163694   | Breast cancer | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer                        | breast cancer that is either locally advanced or metastatic and HER2 negative  | Bloemfontein, Durban, George, Cape Town, Johannesburg, Port Elizabeth, Pretoria | Rachelle Branford<br>Telephone: 011 858 2163/<br>011 858 2037<br>Contact: Melissa Shah,<br>00(847) 938-3885<br>melissa.shah@abbvie.com          | AbbVie                             | Phase 3 | 01 July 2014     | 01 March 2017           |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication       | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations   | Contact (please note some contacts are international) Use NCT number as reference | Sponsor                             | Phase   | Start Date        | Planned Completion Date |
|------------|---|------------------|--|--|---|---|-------------------------------------|---------|-------------------|-------------------------|
| 2016/02/01 | NCT02181413   | Multiple Myeloma | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant   | symptomatic multiple myeloma who already had a bone marrow transplant  | Johannesburg, Pretoria  | Heindrich Pienaar<br>Telephone: 011 612 8600                                      | Millennium Pharmaceuticals, Inc.    | Phase 3 | 01 July 2014      | 01 February 2018        |
| 2016/02/01 | NCT02200614   | Prostate cancer  | Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)   | prostate cancer not responding on castration<br>No metastasis  | George, PE, Johannesburg, Pretoria, Durban, Paarl, Cape Town, Somerset-west | Dr Lance Coetzee - National Principal Investigator<br>Telephone: +27 12 342 9432  | Bayer                               | Phase 3 | 01 September 2014 | 01 June 2020            |
| 2016/02/01 | NCT02213263   | Lymphoma         | A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) | low tumor burden, CD20-positive follicular lymphoma with no prior treatment  | Johannesburg, Pretoria  | Prof L.M Dreosti<br>Telephone: 012 354 1054                                       | Pfizer                              | Phase 3 | 01 September 2014 | 01 December 2017        |
| 2016/02/01 | NCT02220894   | Lung Cancer      | Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)           | advanced or metastatic Non - small cell lung cancer, had no prior systemic chemotherapy for the advanced or metastatic disease                         | Johannesburg  | Contact: Khanyi Mzolo<br>011 655 3140   | Merck Sharp & Dohme Corp.           | Phase 3 | 01 October 2014   | 01 July 2019            |
| 2016/02/01 | NCT02257736   | Prostate cancer  | An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)  | did not receive any chemotherapy for metastatic castration-resistant (low testosterone) prostate cancer  | Bloemfontein, Cape Town, Johannesburg, Pretoria                             | Tel 011 518 7000  | Janssen Research & Development, LLC | Phase 3 | 01 November 2014  | 01 August 2021          |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication           | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations   | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor                   | Phase   | Start Date        | Planned Completion Date |
|------------|---|----------------------|---|--|---|--|---------------------------|---------|-------------------|-------------------------|
| 2016/02/01 | NCT02264990   | Lung Cancer          | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | advanced or metastatic lung cancer and are current or former smokers, but not suitable for radiation or surgery  | Pretoria, Johannesburg, Cape Town, Port Elizabeth, Durban | Contact: Angela M DeLuca, BA 847-936-3354<br>angela.deluca@abbvie.com<br>Contact: Jade M Irving, BA 847-935-2145<br>jade.irving@abbvie.com | AbbVie                    | Phase 3 | 01 September 2014 | 01 November 2017        |
| 2016/02/01 | NCT02272413   | Lung Cancer          | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With advanced Lung Cancer  | Advanced Nonsquamous Non-Small Cell Lung Cancer Recurrent or metastatic disease (Stage IV)   | Cape Town, George, Johannesburg                           | Dr Breedt 0836297693 (ref WWA16924)<br>Boehringer Ingelheim Call Center 1-800-243-0127<br>clintriage.rdg@boehringer-ingelheim.com          | Boehringer Ingelheim      | Phase 3 | 01 July 2015      | 01 March 2019           |
| 2016/02/01 | NCT02352948   | Lung Cancer          | A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer                            | Stage IIIB/ IV lungcancer, already had a platinum-based chemotherapy regimen and at least 1 additional regimen   | Bloemfontein, Cape Town, Johannesburg, Pretoria           | Dr Breedt 0836297693   | AstraZeneca               | Phase 3 | 01 January 2015   | 01 November 2017        |
| 2016/02/01 | NCT02358031   | Head and Neck cancer | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)  | recurrent or metastatic cancer of the head and neck<br>No treatment received for the recurrent or metastatic setting                                   | Johannesburg  | Contact: Khanyi Mzolo 011 655 3140   | Merck Sharp & Dohme Corp. | Phase 3 | 01 March 2015     | 01 September 2018       |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication             | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations   | Contact (please note some contacts are international) Use NCT number as reference   | Sponsor                   | Phase           | Start Date        | Planned Completion Date |
|------------|---|------------------------|---|--|---|---|---------------------------|-----------------|-------------------|-------------------------|
| 2016/02/01 | NCT02364999   | Lung Cancer            | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC  | Newly diagnosed Stage IIIB or IV non-small cell lung cancer had not received chemotherapy for metastatic disease                                       | PE, Johannesburg, Amanzimtoti, Cape Town  | Dr CR Jacobs 021 944 3830   | Pfizer                    | Phase 3         | 01 April 2015     | 01 January 2018         |
| 2016/02/01 | NCT02367040   | Non-Hodgkin's Lymphoma | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)  | CD20 positive Indolent non-Hodgkin's lymphoma that have relapsed after at least 1 prior line of therapy, including rituximab and alkylating agents.    | Johannesburg, Pretoria, George  | clinical-trials-contact@bayerhealthcare.com<br>Marlize Schmitt Theron<br>Telephone: 011 921 5065                            | Bayer                     | Phase 3         | 01 June 2015      | 01 December 2020        |
| 2016/02/01 | NCT02369016   | Non-Hodgkin's Lymphoma | Phase III Copanlisib in Rituximab-refractory iNHL   | must have received two or more prior lines of treatment including rituximab B-cell NHL   | Pretoria, Johannesburg, George  | clinical-trials-contact@bayerhealthcare.com<br>Marlize Schmitt Theron<br>Telephone: 011 921 5065                            | Bayer                     | Phase 3         | 01 September 2015 | 01 August 2017          |
| 2016/02/01 | NCT02370498   | Stomach cancer         | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | metastatic or locally advanced stomach cancer that can't be operated on.   | Johannesburg  | Contact: Khanyi Mzolo: Tel 011 655 3140<br>Zoe Nell Tel 011 655 3000  | Merck Sharp & Dohme Corp. | Phase 3         | 01 May 2015       | 01 February 2018        |
| 2016/02/01 | NCT02379845   | Sarcoma                | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall   | Locally Advanced Soft Tissue Sarcoma of the Extremity and Trunk Wall unresectable tumor or unfeasible carcinological surgery                           | Iatros International, Bloemfontein<br>The Oncology Centre, Durban<br>Gvi Outeniqua Oncology Unit, George<br>Wilgers Oncology Centre, Pretoria | Contact: Mikaela DIMITRIU, PhD<br>mikaela.dimitriu@nanobiotix.com<br>Contact: Elsa BORGHI, MD<br>elsa.borghi@nanobiotix.com | Nanobiotix PharmaEngine   | Phase 2 Phase 3 | 01 February 2015  | 01 June 2017            |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication     | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations                                | Contact (please note some contacts are international) Use NCT number as reference | Sponsor                   | Phase   | Start Date    | Planned Completion Date |
|------------|---|----------------|--|--|--|---|---------------------------|---------|---------------|-------------------------|
| 2016/02/01 | NCT02395172   | Lung cancer    | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet   | Subjects with histologically confirmed Stage IIIb/IV or recurrent NSCLC who have experienced disease progression                                       | Cape Town, PE, Pretoria                  | Dr Breedt: 0836297693   | Merck Serono              | Phase 3 | 15 March 2016 | 01 November 2022        |
| 2016/02/01 | NCT02395172   | Lung Cancer    | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)  | Stage IIIb/IV or recurrent NSCLC who have experienced disease progression  | Cape Town, PE, Pretoria                  | 083 629 7693  | EMD Serono/Merck KGaA     | Phase 3 | 01 March 2015 | 01 October 2021         |
| 2016/02/01 | NCT02447003   | Breast cancer  | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)  | metastatic triple-negative breast cancer   | Johannesburg                             | Contact: Khanyi Mzolo 011 655 3140  | Merck Sharp & Dohme Corp. | Phase 2 | 01 June 2015  | 01 November 2019        |
| 2016/02/01 | NCT02467907   | Cervix cancer  | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Recurrent Metastatic, Cervical Cancer  | Distant metastatic, recurrent or persistent cancer of the cervix that can not be treated with surgery and/or radiation therapy                         | Johannesburg, Pietermaritzburg, Pretoria | Contact: Reference Study ID Number: MO29594 Tel '011 5025027                      | Hoffmann-La Roche         | Phase 2 | 01 July 2015  | 01 January 2019         |
| 2016/02/01 | NCT02494583   | Stomach cancer | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | advanced stomach cancer Has not yet had chemotherapy   | Johannesburg                             | Contact: Khanyi Mzolo 011 655 3140  | Merck Sharp & Dohme Corp. | Phase 3 | 01 July 2015  | 01 April 2019           |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication                    | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail | Locations   | Contact (please note some contacts are international) Use NCT number as reference   | Sponsor                                 | Phase   | Start Date        | Planned Completion Date |
|------------|---|-------------------------------|---|--|---|---|---|---------|-------------------|-------------------------|
| 2016/02/01 | NCT02573324   | Glioblastoma                  | A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification   | Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) positive   | Cape Town   | Contact: Kathy Kim, MS<br>00847-938-0255<br>kathy.kim@abbvie.com<br>Contact: Kysa Meek 00847-938-1090<br>kysa.a.meek@abbvie.com<br>Telephone: 011 858 2163/<br>011 858 2037 | AbbVie Radiation Therapy Oncology Group | Phase 2 | 01 December 2015  | 01 March 2020           |
| 2016/03/30 | NCT02477826   | Lung cancer                   | An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)  | Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer  | Johannesburg 2199   | Adrie Jacobs<br>Telephone: +27 11 808 5488  | BMS                                     | phase 3 | 01 August 2015    | 01 December 2020        |
| 2016/03/30 | NCT02538666   | Lung Cancer                   | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy | Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy                                    | Johannesburg 2199<br>Cape Town 7570<br>George 6530<br>Rondebosch 7700 | Adrie Jacobs<br>Telephone: +27 11 808 5488  | BMS                                     | phase 3 | 01 September 2015 | 01 June 2019            |
| 2016/03/30 | NCT02555657   | triple negative breast cancer | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)   | Metastatic Triple Negative Breast Cancer. Previously treated with an anthracycline and/or taxane in the neoadjuvant/adjuvant or metastatic setting     | Unknown   | MSD (Pty) LTD South Africa Recruiting Midrand, South Africa<br>Contact: Khanyi Mzolo<br>27 11 655 3140  | MSD                                     |         | 01 October 2015   | 01 September 2017       |



| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication                                     | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail                    | Locations   | Contact (please note some contacts are international) Use NCT number as reference | Sponsor   | Phase     | Start Date        | Planned Completion Date |
|------------|---|--|---|---|---|---|---|-----------|-------------------|-------------------------|
| 2016/05/24 | NCT02388906   | Melanoma                                       | Efficiency study of Nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV Melanoma  | Completely removed melanoma by surgery performed within 12 weeks of randomization Stage IIIb/C or Stage IV before complete resection No previous anti-cancer treatment    | Johannesburg, 2199<br>Pretoria, 0181<br>Saxonwold,<br>Johannesburg, 2196<br>Cape Town 7570<br>Rondebosch 7700                                   | Adrie Jacobs<br>Telephone: +27 11 808 5488  | BMS/Ono<br>Pharmaceutical<br>Co/Ltd   | phase 3   | 01 March 2015     | 01 November 2019        |
| 2016/05/24 | NCT02519842   | Chemo induced nausea and vomiting (< 17 years) | A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Subjects Receiving Emetogenic Chemotherapy | Be receiving chemotherapeutic agent(s) associated with moderate or high risk of nausea and vomiting, or a chemotherapy regimen not previously tolerated due to vomiting   | Johannesburg  | Contact: Khanyi Mzolo<br>011 655 3140   | Merck Sharp & Dohme Corp.   | phase 3   | 01 September 2015 | 01 November 2017        |
| 2016/05/24 | NCT02576275   | multiple myeloma                               | A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185).  | active multiple myeloma that can't be treated with stem-cell transplantation due to age (≥65 years old) or any significant coexisting medical condition                   | Johannesburg  | Contact: Khanyi Mzolo<br>27 11 655 3140   | MSD (Pty) LTD<br>South Africa   | phase III | 01 October 2015   | 01 March 2019           |
| 2016/05/24 | NCT02576574   | Non Small Cell Lung Cancer                     | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 100)   | Subjects with histologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) Subjects must not have received any treatment for systemic lung cancer, | GVI Cape Gate<br>Oncology Centre<br>Recruiting<br>Cape Town, Western<br>Cape, South Africa,<br>7570<br>Principal Investigator:<br>Conrad Jacobs | Contact: Sylvia Holdt<br>+27219443830<br>sylvia.holdt@cancercares.co.za           | EMD Serono<br>Research &<br>Development<br>Institute,<br>Inc.   Merck<br>KGaA   EMD<br>Serono | Phase 3   | 01 October 2015   | 01 June 2023            |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication           | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail  | Locations  | Contact (please note some contacts are international) Use NCT number as reference   | Sponsor                            | Phase     | Start Date        | Planned Completion Date |
|------------|---|----------------------|---|---|--|---|------------------------------------|-----------|-------------------|-------------------------|
| 2016/05/24 | NCT02765503   | Head and Neck cancer | Resource-Sparing Curative radiotherapy for locally advanced squamous cell cancer of the head and neck (HYPNO)   | Stage I-IV tumor of oropharynx, hypopharynx, larynx , or oral cavity<br>Must be a candidate for external beam radical radiotherapy<br>Must have no HIV or distant metastasis  | University of Pretoria<br>Pretoria, South Africa   | Contact: Roy Lakier<br>roy.lakier@up.ac.za  | International Atomic Energy Agency | Phase 3   | 01 March 2014     | 01 November 2021        |
| 2016/06/30 | NCT01435018   | Kaposi's Sarcoma     | A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   | HIV-1 infection, Karposi Sarcoma  | Durban Adult HIV CRS (11201)4013 SF<br>Principal Investigator: Umesh Gangaram Lalloo, MD, FRCP<br>University of Witwatersrand Johannesburg | Contact: Fawzia Williamson 27 31 260 4365 amodf1@nu.ac.za<br>Contact: Pauline S Vunandlala, BSc. 27 11 717 2810<br>idsyndicate@witshealth.co.za | AIDS Clinical Trials Group         | phase III | 01 August 2013    | 01 June 2027            |
| 2016/06/30 | NCT01907100   | Mesothelioma         | LUME-Meso: Phase II/III Study of Nintedanib With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy vs Placebo With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for Unresectable Malignant Pleural Mesothelioma | Confirmed malignant pleural mesothelioma (MPM)<br>Previous systemic chemotherapy for MPM  | 1199.93.27001<br>Boehringer Ingelheim Investigational Site<br>Pretoria, South Africa   | Contact: Boehringer Ingelheim Call Center 001-800-243-0127 (USA number) or email<br>clintriage.rdg@boehringer-ingelheim.com                     | Boehringer Ingelheim               | phase III | 01 September 2013 | 01 October 2019         |
| 2016/06/30 | NCT02115282   | Breast cancer        | A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer   | Estrogen receptor (ER) and/or progesterone receptor (PR) positive adenocarcinoma of the breast, stage III/locally advanced or metastatic carcinoma of the breast where local therapy with curative intent is not possible | University Of Pretoria<br>Pretoria, South Africa, 0002   | Contact: Lydia M. Dreosti 27-12-329-1100<br>lydia.dreosti@up.ac.za<br>Principal Investigator: Lydia M. Dreosti                                  | National Cancer Institute (NCI)    | Phase III | 01 April 2014     | 01 July 2017            |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication                 | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail  | Locations  | Contact (please note some contacts are international) Use NCT number as reference   | Sponsor                    | Phase     | Start Date       | Planned Completion Date |
|------------|---|----------------------------|--|---|--|---|----------------------------|-----------|------------------|-------------------------|
| 2016/06/30 | NCT02563002   | Colon cancer               | A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)   | Locally confirmed stage IV colorectal carcinoma, no brain metastases, no immunosuppressive drugs or cortisone used  | MSD (Pty) LTD South Africa<br>Midrand, South Africa  | Contact: Khanyi Mzolo<br>27 11 655 3140   | Merck Sharp & Dohme Corp.  | Phase III | 15 November 2016 | 01 August 2019          |
| 2016/06/30 | NCT02628067   | Advanced cancer            | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)  | Histologically or cytologically-documented, advanced solid tumor. Progression of tumor or intolerance to therapies known to provide clinical benefit. There is no limit to the number of prior treatment regimens | Johannesburg   | Contact: Khanyi Mzolo<br>27 11 655 3140   | MSD (Pty) LTD South Africa | phase II  | 01 December 2015 | 01 April 2021           |
| 2016/06/30 | NCT02657434   | Non Small Cell Lung Cancer | Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer | Histologically or cytologically confirmed, Stage IV non-squamous NSCLC<br>No prior treatment for Stage IV non-squamous NSCLC.<br>No brain metastases  | George, South Africa, 6530<br>Groenkloof, South Africa, 0181<br>Port Elizabeth, South Africa, 6045<br>Pretoria, South Africa, 0157<br>Pretoria, South Africa, 0002 | Reference Study ID Number: GO29438<br><a href="http://www.roche.com/about_roche/roche_worldwide.htm">www.roche.com/about_roche/roche_worldwide.htm</a><br>888-662-6728 (U.S. and Canada)<br><a href="mailto:global.roche.genentechtrials@roche.com">global.roche.genentechtrials@roche.com</a><br>'011 502 5027 | Hoffmann-La Roche          | Phase III | 01 April 2016    | 01 January 2019         |
| 2016/06/30 | NCT02674061   | advanced ovarian cancer    | A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)  | epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, adequate organ function, do not have an active autoimmune disease  | Johannesburg   | Contact: Khanyi Mzolo<br>011 655 3140   | Merck Sharp & Dohme Corp.  | phase II  | 01 February 2016 | 01 March 2020           |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication                       | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail   | Locations   | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor           | Phase     | Start Date      | Planned Completion Date |
|------------|---|----------------------------------|---|--|---|--|-------------------|-----------|-----------------|-------------------------|
| 2016/06/30 | NCT02807636   | Bladder and urinary tract cancer | A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti PD-L1 Antibody) in Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based Therapy | Locally advanced or metastatic transitional cell carcinoma [TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra. No prior chemotherapy for inoperable locally advanced or metastatic cancer. No active or untreated brain metastases | Port Elizabeth, South Africa, 6045<br>Pretoria, South Africa, 0002<br>Sandton, South Africa, 2196 | Reference Study ID Number: WO30070<br><a href="http://www.roche.com/about_roche/roche_worldwide.htm">www.roche.com/about_roche/roche_worldwide.htm</a><br>888-662-6728 (U.S. and Canada)<br><a href="mailto:global.roche.genentech@roche.com">global.roche.genentech@roche.com</a><br>011 502 5027 | Hoffmann-La Roche | phase III | 01 June 2016    | 01 September 2019       |
| 2016/09/13 | NCT02752074   | Melanoma                         | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epcadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma  | Have histologically or cytologically confirmed melanoma<br>Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy  | Johannesburg, Sandton, Groenkloof, Pretoria, Cape Town, Kraaifontein                              | Contact: Incyte Corporation<br>Call Center 001 855 463 3463  | Incyte            | phase III | 01 June 2016    | 01 May 2018             |
| 2016/09/13 | NCT02763566   | Breast Cancer                    | A Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer                   | A diagnosis of HR+, HER2-breast cancer with local recurrent disease not amenable to resection or radiation therapy, or metastatic disease. Postmenopausal.   | Pretoria and Johannesburg   | contact 01-877-CTLILLY (01-877-285-4559, 01-317-615-4559 between 15h00 and 18h00   | Eli Lilly         | phase III | 01 October 2016 | 01 December 2019        |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication           | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail  | Locations  | Contact (please note some contacts are international) Use NCT number as reference                   | Sponsor                    | Phase         | Start Date        | Planned Completion Date |
|------------|---|----------------------|---|---|--|---|----------------------------|---------------|-------------------|-------------------------|
| 2016/11/01 | NCT00725387   | Any Cancer           | Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy (only scan for malignancy, no treatment)   | Patients older than 18-year-old, diagnosed with cancer  | Pretoria Academic Hospital   | Andrei Iagaru 00 650-736-2859<br>aiagaru@stanford.edu   | Stanford University        | observational | 01 August 2007    | 01 December 2018        |
| 2016/11/01 | NCT01479283   | Bone cancer          | Prophylactic Antibiotic Regimens in Tumor Surgery   | primary malignant or aggressive benign bone tumors of the lower extremity, or soft-tissue sarcomas which have invaded the bone; and treatment by surgical excision and endoprosthetic replacement. Older than 12 years. | Grey's Hospital<br>Pietermaritzburg, South Africa<br>Principal Investigator:<br>Reitze Rodseth, MBChB                                | Paula McKay, B.Sc (905) 527-4322 ext 44131<br>mckayp@mcmaster.ca                                    | McMaster University        | observational | 01 January 2013   | 01 December 2019        |
| 2016/11/01 | NCT02579863   | Multiple Myeloma     | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)   | Confirmed diagnosis of active multiple myeloma and measurable disease. Ineligible to receive treatment with auto-Stem cell transplant due to age ( $\geq 65$ years old) or any significant coexisting medical condition | Unknown  | MSD (Pty) LTD South Africa Recruiting Midrand, South Africa<br>Contact: Khanyi Mzolo 27 11 655 3140 | MSD (Pty) LTD South Africa | open label    | 01 October 2015   | 01 March 2019           |
| 2016/11/01 | NCT02823574   | Head and Neck cancer | A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Confirmed squamous cell head and neck cancer Widespread (metastatic) disease, or returned after previous treatment (recurrent)  | Port Elizabeth, Eastern Cape, Site 0036<br>Johannesburg, Gauteng, Site 0017<br>Pretoria, Gauteng, Site 0019<br>Rondebosch, Site 0018 | Clinical.Trials@bms.com<br>Contact: First line of the email MUST contain NCT# and Site #.           | BMS                        | phase II      | 01 September 2016 | 01 October 2018         |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication              | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail  | Locations                    | Contact (please note some contacts are international) Use NCT number as reference   | Sponsor                | Phase   | Start Date       | Planned Completion Date |
|------------|---|-------------------------|--|---|------------------------------|---|------------------------|---------|------------------|-------------------------|
| 2017/03/28 | NCT02750202   | Genital warts           | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (TheraVACCS)  | Female patient > 16 years with vulvo vaginal genital warts, HIV negative or HIV infected and CD4 $\geq$ 300 cells/mm <sup>3</sup> OR viral load controlled OR anti retro-viral (ARV) compliant > 6 months | Pretoria                     | Steve Biko Academic Hospital<br>Contact: Cathy Visser, MSc +27 12 354 3900<br>visser.cathy@gmail.com<br>Principal Investigator: Leon C Snyman, MMedO&G;FCOG | University of Pretoria | phase 3 | 01 July 2016     | 01 June 2019            |
| 2017/03/28 | NCT02899299   | Mesothelioma            | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | pleural malignant mesothelioma not eligible for curative surgery  | Cape Town                    | please email: Clinical.Trials@bms.com<br>First line of the email MUST contain NCT# and Site number 0059   | Bristol-Myers Squibb   | phase 3 | 01 October 2016  | 01 September 2021       |
| 2017/03/28 | NCT03049189   | Neuro-endocrine tumours | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)  | Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin   | Pretoria Steve Biko Hospital | Contact: Dr Konstantin Zherosekov, info@itm-solucin.de<br>Contact: DR Ulrike Schorr-Neufing, info@abx-cro.com   | ITM Solucin GmbH       | phase 3 | 01 February 2017 | 01 May 2021             |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication    | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail  | Locations  | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor | Phase   | Start Date       | Planned Completion Date |
|------------|---|---------------|--|---|--|--|---------|---------|------------------|-------------------------|
| 12/07/2017 | NCT02263508   | Melanoma      | Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)  | <p>intermediate and stage IIIb to IVM1c for whom surgery is not recommended. Subjects must be a candidate for intralesional therapy administration into cutaneous, subcutaneous, or nodal lesions. Subjects with BRAFV600 wild-type tumors without any prior chemotherapy, immunotherapy, or targeted therapy given Prior BRAF inhibitor therapy either alone or in combination with MEK inhibitor as the only prior systemic therapy is allowed</p> <p>Key Exclusion Criteria: Brain metastases. Subjects must not have primary eye or mucosal melanoma, history or evidence of melanoma associated with immunodeficiency states or history of other malignancy within the past 3 years.</p> | <p>Research Site Groenkloof 0181 Johannesburg, 2196 Kraaifontein, 7570 Pretoria, 0002 Pretoria, 0081</p>   | <p>Contact: Amgen Call Center 00 866-572-6436 <a href="mailto:medinfo@amgen.com">medinfo@amgen.com</a></p>   | Amgen   | Phase 3 | 08 December 2014 | 31 December 2018        |
| 12/07/2017 | NCT02322814   | Breast cancer | A Study of Cobimetinib in Combination With Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, and Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-line Treatment for Participants With Metastatic Triple-Negative Breast Cancer | <p>Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease</p>   | <p>Cape Town Oncology Trials, Mary Potter Oncology Centre Groenkloof, Wits Donald Gordon Clinical Trial Site Johannesburg, Langenhoven Drive Oncology Centre Port Elizabeth, Steve Biko Academic Hospital Oncology Pretoria, Eastleigh Breast Care Centre Pretoria</p> | <p>Contact: Reference Study ID Number: WO29479 <a href="http://www.roche.com/about_roche/roche_worldwide.htm">www.roche.com/about_roche/roche_worldwide.htm</a> Tel 00 888-662-6728 Email <a href="mailto:global-roche-genentech-trials@gene.com">global-roche-genentech-trials@gene.com</a></p> | Roche   | Phase 2 | 25 November 2014 | 31 July 2018            |

| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication                       | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail   | Locations   | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor          | Phase         | Start Date        | Planned Completion Date |
|------------|---|----------------------------------|--|--|---|--|------------------|---------------|-------------------|-------------------------|
| 12/07/2017 | NCT02626455   | Lymphoma                         | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)   | Histologically confirmed diagnosis of CD20 positive iNHL. Patients must have relapsed after at least 1 but at most 3 prior lines of therapy, no HIV or hepatitis, no heartfailure                  | Kimberley, Northern Cape, South Africa, 8301  | Contact: clinical-trials-contact@bayer.com<br>Contact: Bayer US toll-free number 00 1-888-84 22937                                       | Bayer            | Phase 3       | 06 January 2016   | 30 September 2021       |
| 12/07/2017 | NCT02853305   | Bladder and urinary tract cancer | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)                         | Advanced/unresectable (inoperable) or metastatic urothelial carcinoma of the renal pelvis, ureter [upper urinary track], bladder, or urethra. No HIV, hepatitis, TB.                               | unknown   | MSD (Pty) LTD South Africa Recruiting Midrand, South Africa<br>Contact: Khanyi Mzolo 27 11 655 3140                                      | MSD              | Phase 3       | 15 September 2016 | 29 January 2019         |
| 12/07/2017 | NCT02956031   | Cervix cancer screening          | Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.  | Exclusion Criteria: Current pregnancy, Hysterectomy, Current or previous treatment for gynaecological cancer   | Pretoria Steve Biko Hospital  | Contact: Greta Dreyer, PhD +(27) 12 354 3900 greta.dreyer@up.ac.za<br>Contact: Cathy Visser, MSc +(27) 12 354 3900 cathy.visser@up.ac.za | Univ of Pretoria | observational | 02 November 2016  | 01 November 2019        |
| 12/07/2017 | NCT02960022   | Prostate cancer                  | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study  | Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. | Site ZA27001 George, South Africa, 6529   | Contact: Astellas Pharma Global Development Tel 00 800-888-7704 ext 5473 email: astellas.registration@astellas.com                       | Astellas         | Phase 2       | 22 December 2016  | 01 July 2021            |
| 12/07/2017 | NCT02993523   | Leukemia                         | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | Acute Myeloid Leukemia (AML), not legible for treatment with a standard cytarabine and anthracycline induction regimen due to age or comorbidities.  | Tshwane District Hospital /ID# 153682 Pretoria<br>Netcare Pretoria East Hospital /ID# 153684 Pretoria | Contact: AbbVie_Call Center 00 847 283 8955 email: abbvieclinicaltrials@abbvie.com   | AbbVie           | phase 3       | 02 February 2017  | 01 February 2020        |



| Added      | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication  | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail       | Locations   | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor     | Phase   | Start Date       | Planned Completion Date |
|------------|---|-------------|---|--|---|--|-------------|---------|------------------|-------------------------|
| 12/07/2017 | NCT03033511   | Lung cancer | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)                                     | extensive-stage disease small cell lung cancer (ED SCLC) with ongoing clinical benefit following completion of 4 cycles of first-line platinum-based therapy | The Oncology Centre /ID# 158872 Durban 4001<br>Langenhoven Drive Oncology Centre /ID# 159126 Port Elizabeth 6045<br>Mary Potter Oncology Centre /ID# 158877 Pretoria 0181<br>Wilgers Oncology Centre /ID# 158873 Pretoria 0081              | Contact: AbbVie_Call Center 00 847 283 8955<br>email: <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>                 | AbbVie      | Phase 3 | 07 February 2017 | 14 November 2019        |
| 12/07/2017 | NCT03069352   | Leukemia    | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Na <sup>+</sup> ve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | Acute Myeloid Leukemia (AML) and is not legible for intensive induction chemotherapy   | Tshwane District Hospital /ID# 157361 Pretoria, South Africa, 0001  | Contact: AbbVie_Call Center 00 847 283 8955<br>email: <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>                 | AbbVie      | Phase 3 | 24-May-17        | 02-Dec-19               |
| 12/07/2017 | NCT03164616   | Lung cancer | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).  | Stage IV NSCLC No prior chemotherapy or any other systemic therapy for metastatic NSCLC.   | Durban, South Africa, 4091<br>Johannesburg, South Africa, 0001<br>Johannesburg, South Africa, 2193<br>Kraaifontein, South Africa, 7570<br>Pretoria, South Africa, 0001<br>Rondebosch, South Africa, 7700<br>Vereeniging, South Africa, 1930 | Contact: AstraZeneca Cancer Study Locator Service 00 1-877-400-4656<br>email: <a href="mailto:AstraZeneca@emergingmed.com">AstraZeneca@emergingmed.com</a> | AstraZeneca | Phase 3 | 01 June 2017     | 31 July 2019            |

| Added    | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication                 | Title  | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail   | Locations   | Contact (please note some contacts are international) Use NCT number as reference  | Sponsor              | Phase  | Start Date       | Planned Completion Date |
|----------|---|----------------------------|--|--|---|--|----------------------|--------|------------------|-------------------------|
| 17/09/27 | NCT01846611   | Gynecology cancers         | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer                                     | adult female patients with platinum-sensitive advanced - relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum - based chemotherapy                                  | Rainbow Oncology Amanzimtoti, GVI Oncology Cape Town, The Oncology Centre Durban, University of Witwatersrand, Department of Medical Oncology Johannesburg, Sandton Oncology CentreJohannesburg, Langenhoven Drive OncologyPort Elizabeth, Mary Potter Oncology Centre - Little Company Of Mary Pretoria, | Contact sites directly or <a href="http://pam.sylogent.com/cr/CR100983">http://pam.sylogent.com/cr/CR100983</a>  | Janssen              | III    | 16 October 2013  | 12 September 2018       |
| 17/09/27 | NCT02379845   | Sarcoma                    | NBTR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall   | Locally Advanced Soft Tissue Sarcoma of the Extremity and Trunk Wall; all grades, including Locally advanced unresectable low grade tumor; Candidate for radiotherapy i.e. unresectable tumor or unfeasible carcinological surgery | Iatros International Bloemfontein, The Oncology Centre Durban, Gvi Outeniqua Oncology Unit George, Wilgers Oncology Centre Pretoria   | Contact: Mikaela DIMITRIU, PhD <a href="mailto:mikaela.dimitriu@nanobiotix.com">mikaela.dimitriu@nanobiotix.com</a><br>Contact: Elsa BORGHI, MD <a href="mailto:elsa.borghini@nanobiotix.com">elsa.borghini@nanobiotix.com</a> | Nanobiotix           | II/III | 01 February 2015 | 01 December 2019        |
| 17/09/27 | NCT02477826   | Non-small cell lung cancer | An Investigational Immunotherapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy   | Johannesburg, Pretoria, Vereeniging   | Clinical.Trials@bms.com<br>First line of the email MUST contain NCT# and Site #.   | Bristol-Myers Squibb | III    | 01 August 2015   | 1 Decembre 2020         |

| Added    | Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search this NCT Number for more detail | Indication          | Title   | abbreviated in and exclusion criteria - Go to <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> and search NCT Number for more detail      | Locations   | Contact (please note some contacts are international) Use NCT number as reference | Sponsor   | Phase | Start Date      | Planned Completion Date |
|----------|---|---------------------|---|---|---|---|-----------|-------|-----------------|-------------------------|
| 17/09/27 | NCT02809053   | Follicular lymphoma | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma | Asymptomatic patients with Low Tumor Burden Follicular Lymphoma, no previous treatment with any chemotherapy and/or rituximab or other monoclonal antibody. | Pretoria  | info@archigenbio.com  | Archigen  | III   | 18 January 2017 | 01 July 2018            |
| 17/09/27 | NCT03155997   | Breast cancer       | A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer  | Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer                          | Cape Town, George, Johannesburg, Port Elizabeth, Pretoria | 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559)                                    | Eli Lilly | III   | 12 July 2017    | 28 June 2027            |